You are here: Industry Insights > Ad26.COV2-S

News List

Aspen Pharmacare to manufacture Covid-19 vaccine candidate with J&J pharmaceutical-technology
November 05, 2020
Aspen’s South African subsidiary Aspen Pharmacare has signed a preliminary agreement with two Johnson & Johnson (J&J) subsidiaries for the technical transfer and proposed commercial manufacture of their Covid-19 vaccine candidate.
J&J Accelerates COVID-19 Vaccine Candidate americanpharmaceuticalreview
June 22, 2020
Johnson & Johnson announced through Janssen Pharmaceutical, it has accelerated the initiation of the Phase 1/2a first-in-human clinical trial of its investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant.
Johnson & Johnson announces acceleration of its COVID-19 vaccine candidate; Phase 1/2a clinical trial to begin in second half of July worldpharmanews
June 11, 2020
Johnson & Johnson announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/2a first-in-human clinical trial of its investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant.